In the ongoing battle against antibiotic resistance, a new study published in Engineering by Zhuoren Ling’s research team unveils a promising triple combination of antibiotics that significantly ...
Titled "The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers," the research sheds light on a ...
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...
Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...
Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.
Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, announced plans to unveil the company’s lead candidate at the upcoming Interdisciplinary ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that ...
The success of modern medicine rests on the ability to control infections. But decades of antibiotic overuse—in hospitals, communities, and farms—have fueled a global surge in resistant microbes.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Pfizer Inc.’s Emblaveo (aztreonam-avibactam), an antibiotic combination that would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback